TP53 and hepatocellular carcinoma: In our study, somatic mutation analysis in both the TCGA-LIHC and LIRI-JP cohorts demonstrated significant enrichment of the TP53 mutation in stemness subtype I. The mRNAsi levels of HCC patients with mutant TP53 were also significantly higher than the mRNAsi levels of other HCC patients.